Halozyme Therapeutics, Inc.

Investor Update

NASDAQ: HALO

October 24, 2024

Forward Looking Statements

In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company's expected future financial performance including expectations for future royalty revenues. Forward-looking statements related to the Company's ENHANZE® drug delivery technology intellectual property include expectations for future patent issuance (including co-formulation patents), length of patent terms and patent expirations and the expected impact such patents may have on the duration, durability and amounts of future royalty payments the Company may receive from licensing such intellectual property, including the expected royalty rate the Company receives under the Janssen license on sales of products co-formulated with ENHANZE® in the U.S. and European countries where the patent is validated. Forward-looking statements also include the Company's expectation that the European patent opposition decision mentioned in this presentation will not impact the patentability standard for obtaining future collaboration patents and the potential for co-formulation patents to extend royalty payment periods and maintain royalty rates. Forward-looking statements regarding the Company's MDASE™ patent portfolio include statements regarding the potential for new licensing opportunities for the Company, the expected exclusivity of these patents through 2032 for OUS countries and 2034 in the U.S., and the potential for using the MDASE™ technology to enable subcutaneous delivery of drugs and biologics and in combination with the Company's high volume autoinjector technology. These forward-looking statements are typically, but not always, identified through use of the words "expect," "believe," "enable," "may," "will," "could," "can," "durable," "growth," "innovate," "develop," "vision," "potential," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning and involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Actual results could differ materially from the expectations contained in these forward-looking statements as a result of several factors, including unexpected early expiration or termination of the patent terms for the Company's ENHANZE® drug delivery technology or its MDASE™ technology, unexpected levels of revenues (including royalty revenue received from our collaboration with Janssen and other partners), unexpected results or delays in the Company's ability to license its MDASE™ intellectual property, unexpected delays in the issuance of the Company's pending or future collaboration patent applications, in obtaining new co-formulation or proprietary intellectual property, or in the development, regulatory review or commercialization of our partners' ENHANZE® products, regulatory approval requirements, unexpected adverse events or patient outcomes and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". The Company undertakes no obligation to update or revise any forward-looking statements or any other information contained herein.

Agenda

Janssen European Patent Opposition Proceedings

Halozyme's Patent Portfolio Update

Question & Answer Session

Janssen European Patent Opposition – Takeaways

- Maintaining projected royalties for sales of DARZALEX® SC in Europe into 2032
- Maintaining projected royalties for DARZALEX FASPRO® in the United States
- No impact to patentability standard and expectations for future collaboration patents

Janssen European and U.S. Collaboration Patents

European Collaboration Patents		
EP 3 370 770	Granted Patent	Opposition Appeal 5/6/25
EP 3 827 845	Granted Patent	Opposition Appealable
EP 4 085 929	Published Application	Not Granted/No Opposition

U.S. Granted Collaboration Patents		
US 10,385,135	US 11,566,079	US 11,708,420
US 10,781,261	US 11,708,419	US 11,732,051
Not Impacted by European Proceedings		

DARZALEX® SC and DARZALEX FASPRO® – Projected Royalty Term and Rate Unchanged

Product Name	Co-formulation Patent Status & Anticipated Impact	First Commercial Sale
DARZALEX® SC (OUS)^	Granted; royalty 12 years post first commercial sale	
DARZALEX FASPRO® (U.S.)	Granted; royalty 12 years post first commercial sale	



Royalty terms are projected based on valid, granted collaboration patents in the United States and Europe

Projected royalty term into 2032 in Europe unless all Janssen's European collaboration patents are revoked by final, unappealable decisions

No impact to U.S. royalty term, as different collaboration patents apply in the United States

^ Royalty reduction (i) in March 2029 for 37 European countries; and (ii) other countries in March 2024.

Halozyme

Collaboration Patents Expected from Licensee Collaborations



Collaboration patents cover the licensed product, including:

- Product formulations
- Product dosing schedules and regimens
- Use of licensed product for treatment of disease/conditions



Patents are granted for innovations that are "non-obvious" or when there are “non-obvious” results including:

- Improved pharmacokinetic profile
- Improved therapeutic results
- Improved stability, improved drug potency or retention of potency
- Decoupling of pharmacokinetic and pharmacodynamic response
- Altered duration of release or effect
- Reduction in adverse events

Janssen opposition does not impact patentability standard for future collaboration products

Introducing Halozyme's MDASE™ Patents

MDASE™ patents broadly cover modified human hyaluronidases for potential use in enabling subcutaneous delivery of drugs and biologics



Halozyme's MDASE™ Patent Portfolio – Extensive Portfolio

Result of groundbreaking R&D by Halozyme over many years – making thousands of modifications to human hyaluronidases and characterizing the effects on stability and activity

99

Patents or pending patent applications worldwide

Exclusivity[1] through

2032 (OUS)

2034 (U.S.)



[1]Select U.S. patents expire in 2034

Halozyme